OssDsign awarded long-term agreement with Premier, Inc.

Uppsala, Sweden, April 2 – OssDsign AB (publ.) today announces that the company has been awarded a new group purchasing (GPO) agreement for Bone and Bone Substitute Implantable Products with Premier, Inc., a leading U.S. healthcare improvement company uniting an alliance of approximately 4,350 U.S. hospitals and health systems and more than 300,000 other providers and organizations. The agreement is for a period of three years.

Effective July 1, 2024, the agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for OssDsign’s nanosynthetic bone graft OssDsign Catalyst^®.

“We are very pleased to have been awarded a long-term agreement with Premier for our innovative synthetic bone graft. It is a clear recognition of our market offering, and opens up a large, valuable network providing many more hospitals and patients access to OssDsign Catalyst,” said Morten Henneveld, CEO, OssDsign.

OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue in the body. 12-month results from the clinical study TOP FUSION, published in the peer-reviewed journal Biomedical Journal of Scientific & Technical Research, show a 93 % spinal fusion rate as well as improvements in quality of life and pain following surgery with OssDsign Catalyst.

Premier is a healthcare improvement company uniting an alliance of approximately 4,350 U.S. hospitals and health systems and more than 300,000 other providers and organizations. By providing integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost.